Stocks News

LAST PRICE
125.7400
TODAY'S CHANGE (%)
Trending Up1.7600 (1.4196%)

Bid / Lots
123.1600/ 1
Ask / Lots
132.1900/ 1
Open / Previous Close
124.9100 / 123.9800
Day Range
Low 123.7600
High 126.2800
52 Week Range
Low 103.6300
High 157.9799
Volume
561,776
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Neurocrine Biosciences Presents New KINECT(R)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Thursday Nov 07, 2024 by PR Newswire
  8:30AM ET on Thursday Nov 07, 2024 by PR Newswire
  Companies Mentioned: NBIX
  -- Data Support Positive Impact ofINGREZZA in People With Huntington's Disease Chorea
  -- Findings Presented at the 2024 Annual Meeting of the Huntington Study Group
  Neurocrine Biosciences, Inc.(Nasdaq: NBIX)today presented subgroup analyses and data from the KINECT(R)-HD study showing the impact of INGREZZA(R) (valbenazine) capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington's disease. The subgroup analysis showed consistent efficacy in reducing chorea compared to placebo across all identified subgroups, categorized by demographics and baseline assessment scores. A separate data analysis showed improvements in some aspects of emotional health with no worsening of psychiatric symptoms. This research will be shared at the 2024 Annual Meeting of the Huntington Study Group in Cincinnati.
- Neurocrine Biosciences Presents New KINECT(R)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself.
Nov 5, 2024
- Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire
  4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire
  Companies Mentioned: NBIX
  2024 UBS Global Healthcare Conference on November 12
  Stifel 2024 Healthcare Conference on November 18
  Jefferies London Healthcare Conference on November 19
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in November.
- Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences to Participate at Investor Conferences in November
  
  PR Newswire
  
  SAN DIEGO, Nov. 5, 2024
  
  2024 UBS Global Healthcare Conference on November 12
Nov 4, 2024
- Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Monday Nov 04, 2024 by PR Newswire
  8:30AM ET on Monday Nov 04, 2024 by PR Newswire
  Companies Mentioned: NBIX
  -- Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients
  Neurocrine Biosciences, Inc.(Nasdaq: NBIX)presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA(R) (valbenazine) capsules. These data showed significant improvements in functional, social, emotional and health-related quality of life measures in Phase 3 and 4 studies and improvements in functional, social, independence, emotional and physical aspects of patients' lives and antipsychotic adherence in real-world practice. This research was shared at the 2024 Psych Congress in Boston.

Today
- MEDP Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 1 hour ago by Dow Jones
  1 hour ago by Dow Jones
  Companies Mentioned: MEDP
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP, from 8 hours ago by Dow Jones
  8 hours ago by Dow Jones
  Companies Mentioned: MEDP
- Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: MEDP
- Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation, from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
  Companies Mentioned: MEDP
- Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing, from 16 hours ago by MT Newswires
  16 hours ago by MT Newswires
  Companies Mentioned: EXEL
Yesterday
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: EXEL
- MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Medpace Holdings, Inc. and Encourages Investors to Contact the Firm, from 4:00PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:00PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: MEDP
- The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Medpace Holdings Inc For Securities Law Violations, from 11:02AM ET on Thursday Nov 07, 2024 by Dow Jones
  11:02AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: MEDP
- Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation, from 10:02AM ET on Thursday Nov 07, 2024 by Dow Jones
  10:02AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: MEDP
- Notice of Investigation Against MEDP: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 10:01AM ET on Thursday Nov 07, 2024 by Dow Jones
  10:01AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: MEDP

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Yesterday

Neurocrine Biosciences Presents New KINECT(R)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Thursday Nov 07, 2024 by PR Newswire

Neurocrine Biosciences Presents New KINECT(R)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 5, 2024

Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire

Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones

Nov 4, 2024

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Monday Nov 04, 2024 by PR Newswire

Peers Headlines

Today

MEDP Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 1 hour ago by Dow Jones

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medpace Holdings, Inc. - MEDP, from 8 hours ago by Dow Jones

Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm, from 9 hours ago by Dow Jones

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation, from 10 hours ago by Dow Jones

Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing, from 16 hours ago by MT Newswires

Yesterday

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones

MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Medpace Holdings, Inc. and Encourages Investors to Contact the Firm, from 4:00PM ET on Thursday Nov 07, 2024 by Dow Jones

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Medpace Holdings Inc For Securities Law Violations, from 11:02AM ET on Thursday Nov 07, 2024 by Dow Jones

Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation, from 10:02AM ET on Thursday Nov 07, 2024 by Dow Jones

Notice of Investigation Against MEDP: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 10:01AM ET on Thursday Nov 07, 2024 by Dow Jones